CVRx, Inc. (CVRX)
Healthcare · NMS
Fundamentals
Valuation and ratings
CVRx, Inc. trades at USD4.74, which is 60% above the USD1.91 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 37 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
CVRX earnings and analyst estimates
Recommendation mix, 7 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRX passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$1.87M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.08M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$850.5K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$251.9K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$182.6K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is CVRx, Inc. (CVRX) undervalued?
Against our discounted cash flow estimate of USD1.91, CVRX at USD4.74 is 60% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own CVRX?
7 of the institutions we track reported a position in CVRX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does CVRX report earnings next?
CVRx, Inc. is scheduled to report on 4 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for CVRX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.